<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="581">
  <stage>Registered</stage>
  <submitdate>15/06/2005</submitdate>
  <approvaldate>15/06/2005</approvaldate>
  <nctid>NCT00114556</nctid>
  <trial_identification>
    <studytitle>The Effect of Zoledronic Acid on Bone Density in Liver Transplant Patients</studytitle>
    <scientifictitle>The Effect Of The Bisphosphonate, Zoledronic Acid, On Bone Density In Liver Transplant Patients  A Prospective, Randomised, Controlled Clinical Trial</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>CZOL446 AU02</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Osteoporosis</healthcondition>
    <healthcondition>Liver Transplantation</healthcondition>
    <healthcondition>Fractures</healthcondition>
    <conditioncode>
      <conditioncode1>Musculoskeletal</conditioncode1>
      <conditioncode2>Osteoporosis</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - zoledronic acid

Treatment: drugs: zoledronic acid


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>bone density</outcome>
      <timepoint />
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>bone turnover markers</outcome>
      <timepoint />
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Greater than 17 years of age</inclusivecriteria>
    <inclusiveminage>17</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>70</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Concurrent treatment, or within the past 12 months, with drugs known to affect bone
             metabolism

          -  Hypocalcemia

          -  Renal impairment (creatinine &gt;1.5x ULN)</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate />
    <actualstartdate>1/02/2000</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW</recruitmentstate>
    <hospital>Royal Prince Alfred Hospital - Sydney</hospital>
    <postcode>2050 - Sydney</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Royal Prince Alfred Hospital, Sydney, Australia</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Commercial sector/Industry</othercollaboratortype>
      <othercollaboratorname>Novartis</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Following liver transplantation, rapid bone loss occurs, particularly within the first 6
      months post-transplant. This may be associated with fractures, most notable vertebral. The
      ability to assess osteoporosis therapies in this system may provide useful information for
      osteoporosis management in general.

      Hypotheses:

        1. That treatment with the bisphosphonate, zoledronate, at the time of liver
           transplantation and at 1 month post-transplantation will prevent the early
           transplant-related bone loss (measured by bone densitometry and biochemical bone markers
           at 3 months) seen in patients who are not treated with a bisphosphonate

        2. That continuing treatment with zoledronate at 3 monthly intervals for a total duration
           of 12 months will result in further improvements in bone density beyond that seen at 3
           months

        3. That calcium and vitamin D (vit D) supplementation of liver transplant patients does not
           prevent marked bone loss following transplantation.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00114556</trialwebsite>
    <publication>McDonald JA, Dunstan CR, Dilworth P, Sherbon K, Sheil AG, Evans RA, McCaughan GW. Bone loss after liver transplantation. Hepatology. 1991 Oct;14(4 Pt 1):613-9.
</publication>
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Geoffrey McCaughan, PhD, MB BS</name>
      <address>Royal Prince Alfred Hospital, Sydney, Australia</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>